V. Byrnes

发表

Attempted prophylaxis of human immunodeficiency virus type 1 infection in chimpanzees with a nonnucleoside reverse transcriptase inhibitor.

W. Schleif, E. Roth, K. Murthy, 1994, AIDS research and human retroviruses.

Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors

J. Condra, W. Schleif, A. Rhodes, 1993, Antimicrobial Agents and Chemotherapy.

A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group.

J. Kappes, M. Saag, W. Schleif, 1993, The New England journal of medicine.

Turnover of circulating virion RNA and of cell-associated viral DNA reflects active viral replication in human immunodeficiency virus type 1-infected individuals

S. Staszewski, E. Emini, F. Massari, 1995, Journal of virology.

A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase

Michael S. Saag, George M. Shaw, J. Kappes, 1993 .

A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors

J. Condra, W. Schleif, E. Emini, 1993, Antimicrobial Agents and Chemotherapy.

HIV and multidrug resistance

J. Condra, D. Graham, E. Emini, 1993, Nature.

A system to analyze and identify inhibitors of HIV-1 gene regulation using a defective integrated provirus.

V. Byrnes, D. Hazuda, 1996, Methods in enzymology.

Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors

E A Emini, J. Condra, W. Schleif, 1994, Antimicrobial Agents and Chemotherapy.

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

P. Anderson, W. Schleif, E. Emini, 1995, Antimicrobial agents and chemotherapy.

The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.

J. Condra, W. Schleif, E. Emini, 1994, Archives of virology. Supplementum.

Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.

S. Staszewski, W. Schleif, E. Emini, 1995, The Journal of infectious diseases.